Multi-institutional prospective feasibility study to explore tolerability and efficacy of oral nutritional supplements for patients with gastric cancer undergoing gastrectomy (CCOG1301)

• Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2017-07, Vol.20 (4), p.718-727
• Main Authors: Kobayashi, Daisuke, Ishigure, Kiyoshi, Mochizuki, Yoshinari, Nakayama, Hiroshi, Sakai, Mitsuru, Ito, Seiji, Kojima, Hiroshi, Kajikawa, Masaki, Ando, Masahiko, Kodera, Yasuhiro
• Format: Article
• Language: English
• Subjects: Abdominal Surgery; Adult; Aged; Aged, 80 and over; Body composition; Body weight; Body weight loss; Cancer Research; Dietary supplements; Enteral Nutrition - methods; Feasibility Studies; Female; Gastrectomy; Gastrectomy - adverse effects; Gastric cancer; Gastroenterology; Humans; Male; Malnutrition; Malnutrition - etiology; Malnutrition - prevention & control; Medicine; Medicine & Public Health; Middle Aged; Oncology; Oral administration; Original Article; Postoperative Complications - etiology; Postoperative Complications - prevention & control; Prospective Studies; Stomach Neoplasms - surgery; Surgery; Surgical Oncology
• ISSN: 1436-3291; 1436-3305
• DOI: 10.1007/s10120-016-0668-3

Background Postoperative malnutrition after gastrectomy is deemed inevitable, which could have prejudicial influence on survival for gastric cancer patients. A prospective feasibility study was conducted to evaluate the efficacy of postoperative oral nutritional supplements. Methods Stage I–III gastric cancer patients who underwent distal or total gastrectomy received oral administration of Racol ®  NF (Otsuka Pharmaceutical Factory, Japan), a liquid enteral nutritional formula, as a supplement to regular meals. Racol ®  NF administration at a recommended dosage of 400 kcal/400 ml per day was started within 7 days postoperatively and was continued for 3 months postoperatively. The primary end point was ratio of the weight loss at 3 months postoperatively to the preoperative body weight (body weight loss ratio). Secondary end points were the adherence to Racol ®  NF therapy and changes in body composition. Results One hundred eighteen patients were registered before surgery, 82 of whom were eligible for efficacy analyses. The average rate of body weight loss after 3 months postoperatively was 8.3%. The mean daily intake of Racol ®  NF was 211 ml. There was a significant correlation between adherence to Racol ®  NF therapy and body weight loss ratio ( P